Compare Peloton Interactive Inc (PTON) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Peloton Interactive Inc vs Viatris Inc — how do they compare? Peloton Interactive Inc trades at $4.91 (market cap $2.13B), while Viatris Inc trades at $17.4 (market cap $20.12B). The key difference: Viatris Inc is far larger — about 9.4× Peloton Interactive Inc's market cap, and Viatris Inc pays a 2.74% dividend while Peloton Interactive Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Peloton Interactive Inc for 37 Days and Viatris Inc for 57 Days on average.
| PTON | VTRS | |
|---|---|---|
Market Cap | $2.13B | $20.12B |
Volume | 8,365,857 | 7,543,511 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.86 | $18.27 |
52-Week Low | $3.71 | $9.74 |
Typical Hold Time | 37 Days | 57 Days |
Enterprise Value | $2.64B | $32.24B |
Dividend Yield | — | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Peloton Interactive (PTON) trades at $4.92, up 1.03% for the day, as the company shows signs of operational improvement with positive operating cash flow of $333M in 2025. The stock remains in a bearish technical trend with negative shareholder equity of -$413.7M, though recent product launches including the foldable Tread Flex aim to broaden market appeal. Revenue declined to $2.49B in 2025 with a net loss of $118.9M, but profitability metrics show gradual improvement from previous years.
While PTON faces significant challenges including high debt levels and declining membership, the company achieved its first profitable year in 2026 with $63M net income. Analyst consensus remains cautiously optimistic with a $8.00 price target representing 63% upside potential. Key risks include execution of the turnaround strategy and competitive pressure in the connected fitness market.
Viatris (VTRS) trades at $17.44, down 0.57% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue trends show a slight decline from $16.3B in 2022 to $14.3B in 2025, but net losses have widened significantly, reaching -$3.51B in 2025. Positive cash flow generation and a dividend payment scheduled for September 2026 highlight financial stability amid profitability challenges.
The outlook for VTRS is mixed; analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside, supported by strong cash flow and recent product approvals. However, persistent net losses, high P/E ratio of 236.2, and substantial long-term debt of $14.04B pose risks. Investors should weigh the potential for operational turnaround against ongoing profitability concerns and competitive pressures in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
